X4 Pharmaceuticals (XFOR) Enterprise Value (2019 - 2026)

X4 Pharmaceuticals (XFOR) has reported Enterprise Value for 8 consecutive years, with $394.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Enterprise Value rose 1738.99% year-over-year to $394.9 million; the trailing twelve-month figure through Jun 2026 stood at $394.9 million (up 1738.99% YoY), and the FY2025 full-year result was -$47.9 million, down 168.68% from the prior year.
• Enterprise Value rose to $394.9 million in Q2 2026 per XFOR's latest filing, from $304.7 million in the prior quarter.
• Across five years, Enterprise Value topped out at $9.4 billion in Q2 2023 and bottomed at -$47.9 million in Q4 2025.
• Historically, Enterprise Value has averaged $2.3 billion across 5 years, with a median of $1.2 billion in 2022.
• The sharpest annual moves came in 2025 and 2026: Enterprise Value sank 168.68% in 2025, then soared 38136.98% in 2026.
• Over 5 years, Enterprise Value stood at $1.8 billion in 2022, then soared by 147.0% to $4.4 billion in 2023, then sank by 98.41% to $69.7 million in 2024, then tumbled by 168.68% to -$47.9 million in 2025, then soared by 924.88% to $394.9 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered $394.9 million, $304.7 million, and -$47.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.